PepGen (PEPG) Insider Joshua Resnick Buys 34,000 Shares

Insider Buying and Selling at PepGen Inc.

PepGen Inc. (NasdaqGS: PEPG) insider Joshua Resnick purchased 34,000 shares of the biotechnology company on June 18, 2026. This transaction follows a pattern of parallel insider activity on the exact same date, with multiple company insiders also picking up 34,000 shares apiece.

Insider Buying and Selling at PepGen Inc.

The transaction by Joshua Resnick on June 18, 2026, matched identical purchases made on that day by fellow insiders Howard Mayer, Mitchell Finer, Habib Dable, and Lisa Wyman, each of whom also acquired 34,000 shares. These clustered insider moves come as the clinical-stage biotech firm continues to advance its pipeline of treatments for severe neuromuscular diseases.

Stock Trades Near Recent Lows

Shares of PepGen changed hands at $1.83 on Tuesday, hovering well below the 50-day moving average of $2.67 and the 200-day moving average of $3.52. The stock has traded in a 52-week range between a low of $1.31 and a high of $7.80. With a market capitalization of roughly $196.7 million, the company operates without a meaningful positive P/E ratio as it remains in a clinical development stage.

Analysts Set New Price Targets

Analyst coverage remains generally optimistic despite the lower share price. On September 9, 2026, HC Wainwright & Co. reiterated its buy rating on the stock with a price target of $20.00. Across the broader analyst community, the stock carries a consensus recommendation key of strong_buy, backed by a mean price target of $10.19 based on eight analyst opinions.

Inside PepGen's Pipeline

Founded in 2018 and headquartered in Boston, Massachusetts, PepGen focuses on developing oligonucleotide therapeutics for severe neuromuscular and neurologic conditions. Its clinical pipeline features therapies such as PGN-EDODM1 and FREEDOM2-DM1 for myotonic dystrophy type 1, alongside ongoing open-label extension studies.

What to Watch at PepGen Inc.

Investors are keeping an eye on the company's clinical trial progress and its next scheduled financial report, which is expected on November 11, 2026. Because insider purchases are reported after the transaction date under SEC rules, these filings provide a retrospective look at leadership activity rather than real-time trading signals.